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Abstract
Background: In pain processing, long term synaptic changes play an important role, especially during chronic
pain. The immediate early gene Arc/Arg3.1 has been widely implicated in mediating long-term plasticity in
telencephalic regions, such as the hippocampus and cortex. Accordingly, Arc/Arg3.1 knockout (KO) mice show a
deficit in long-term memory consolidation. Here, we identify expression of Arc/Arg3.1 in the rat spinal cord using
immunohistochemistry and in situ hybridization following pain stimuli.
Results: We found that Arc/Arg3.1 is not present in naïve or vehicle treated animals, and is de novo expressed in
dorsal horn neurons after nociceptive stimulation. Expression of Arc/Arg3.1 was induced in an intensity dependent
manner in neurons that were located in laminae I (14%) and II (85%) of the spinal dorsal horn. Intrathecal injection
of brain derived neurotrophic factor (BDNF) also induced expression of Arc/Arg3.1. Furthermore, 90% of Arc/Arg3.1
expressing neurons also contained the activity marker c-Fos, which was expressed more abundantly.
Preproenkephalin mRNA was found in the majority (68%) of the Arc/Arg3.1 expressing neurons, while NK-1 was
found in only 19% and GAD67 mRNA in 3.6%. Finally, pain behavior in Arc/Arg3.1 KO mice was not significantly
different from their wild type littermates after application of formalin or after induction of chronic inflammatory
pain.
Conclusions: We conclude that Arc/Arg3.1 is preferentially expressed in spinal enkephalinergic neurons after
nociceptive stimulation. Therefore, our data suggest that Arc/Arg3.1 dependent long term synaptic changes in
spinal pain transmission are a feature of anti-nociceptive, i.e. enkephalinergic, rather than pro-nociceptive neurons.
Background
The experience of pain is usually initiated by the acti-
vation of nociceptors, which are the peripheral termi-
nations of nociceptive ganglion neurons. The central
projections of these neurons enter the dorsal horn of
the spinal cord to terminate on second order neurons
[1]. After strong nociceptive stimulation these neurons
may show an enhanced responsiveness to afferent
inputs, which may last for several hours [2-4]. The
mechanism underlying this enhanced responsiveness is
similar to that of long-term potentiation (LTP) [5],
which is a form of activity dependent plasticity that
has been investigated extensively in other parts of the
CNS, especially in the hippocampus [6]. Another form
of activity dependent plasticity is long-term depression
(LTD), a state of decreased sensitivity of neurons.
Whether LTP or LTD is produced in the spinal noci-
ceptive system depends on many variables, including
the type of activity in nociceptive afferents [2]. For
long term changes to become persistent it is essential
that activity regulated genes, including immediate early
genes (IEG), orchestrate a cascade of transcriptions
and subsequent protein synthesis [7]. The first IEG
that was found to be strongly increased in spinal neu-
rons after a nociceptive stimulus is c-Fos [8]. This IEG
is now widely used for the identification of activated
nociceptive neurons [9]. Other IEGs that have been
implicated in plastic changes are c-Jun, Jun-d, Krox 24
and Homer 1a [10,11]. Recently it has become clear
that in cortex, hippocampus and other higher brain
centers, the IEG named Arc/Arg3.1 (activity regulated
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cytoskeleton-associated protein/activity regulated gene
3.1) plays a crucial role in activity dependent synaptic
plasticity [12]. Moreover, Arc/Arg3.1 is critically
involved in processes essential for synaptic structural
rearrangement such as LTP, LTD and homeostatic
scaling of AMPA receptors [13,14]. These mechanisms
are also essential in spinal processing [15], and dys-
functional forms of activity dependent plasticity such
as LTP and LTD that lead to persistent changes in
neuronal sensitivity, may underlie chronic pain disor-
ders [16]. Therefore, in this study we set out to investi-
gate the role of Arc/Arg3.1 in nociceptive processing
in the spinal cord.
Our findings show that Arc/Arg3.1 is not expressed at
detectable levels in naïve spinal cord. However, after
peripheral nociceptive stimulation we found de novo
expression of Arc/Arg3.1 in a limited number of neu-
rons in the superficial dorsal horn, depending on the
type of stimulus. Further, Arc/Arg3.1 is predominantly
expressed in spinal interneurons located in lamina II
and many of these neurons also contain the opioid neu-
rotransmitter enkephalin. Finally, we found that the pain
behavior in Arc/Arg3.1 knockout (KO) mice after noci-
ceptive stimuli was not significantly different from their
wild type (WT) littermates.
Results
General observations
In the spinal cord of naïve rats and mice there was no
detectable expression of Arc/Arg3.1 mRNA or protein
when using in situ hybridization (ISH) and immuno-
histochemistry (IHC), respectively. However, after
application of a peripheral nociceptive stimulus to the
hind paw, Arc/Arg3.1 was expressed in a limited num-
ber of cells in the superficial layers of the lumbar dor-
sal horn. ISH using the alkaline phosphatase (AP)
reaction produced a bluish/brownish reaction product
in the cytoplasm and in some occasions in the nucleus
and primary dendrites of Arc/Arg3.1 mRNA expressing
neurons (Fig. 1A,B). Arc/Arg3.1 protein, visualized by
bright field IHC, was present primarily in the cyto-
plasm, occasionally combined with nuclear labeling or
labeling in proximal dendrites (Fig. 1C). Applying
fluorescent IHC for Arc/Arg3.1 protein produced very
similar labeling characteristics. In order to ascertain
that Arc/Arg3.1 is expressed in neurons rather than in
glial cells, we combined FISH for Arc/Arg3.1 mRNA
with fluorescent IHC for NeuN, which is a specific
marker for neuronal cells (Fig. 1D). It was found
that 95% ± 1.3 (SEM) of the cells expressing Arc/
Arg3.1 mRNA also expressed NeuN (99% ± 0.4 for
Figure 1 Arc/Arg3.1 is only expressed in the superficial dorsal horn. Light micrographs showing the distribution of neurons expressing Arc/
Arg3.1 mRNA (A, B) or protein (C) in the rat spinal dorsal horn after peripheral stimulation with 25% mustard oil gauze wrapped around one
hind paw for 2 hours. Note that many of the Arc/Arg3.1 labeled neurons are located in laminae I&II, and very few labeled neurons are present
below lamina II. D, Fluorescent micrograph showing the expression of Arc/Arg3.1 mRNA and its colocalization with the neuronal marker NeuN.
Arrowheads indicate Arc/Arg3.1 mRNA and NeuN double labeled neurons. Scale bar: 50 μm (A and D); 25 μm (B); 100 μm (C).
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25% MO/1 h, n = 4; 95% ± 3.3 for 25% MO/2 hrs, n =
5; 94% ± 2.8 for CFA for 1.5 hrs, n = 4).
For both ISH and IHC, we observed that the intensity
of the labeled neurons varied in a single section. We did
not observe any labeling indicative of localization of
Arc/Arg3.1 in intermediate or distal dendrites. Although
labeling patterns obtained with ISH and IHC were iden-
tical, labeling efficiency was higher for ISH than for
IHC. Therefore, ISH was used for the quantification of
neurons expressing Arc/Arg3.1. The specificity of our
detection techniques was assessed by omitting the
probes/primary antibodies in the ISH and IHC proce-
dures, respectively, and by applying ISH and IHC on
spinal tissue of Arc/Arg3.1 KO mice. These experiments
did not show any labeling in the spinal cord. ISH per-
formed on cortex of naïve rats showed Arc/Arg3.1
mRNA labeling in the cortex and the hippocampus as
previously reported [17].
Distribution and quantification of Arc/Arg3.1 mRNA
expressing neurons in the spinal cord following
nociceptive stimulation
Several types of nociceptive stimuli applied to the hind
paw induced Arc/Arg3.1 mRNA expressing neurons on
the ipsilateral side (Fig. 2) but not on the contralateral
side of the lumbar superficial dorsal horn. A single sub-
cutaneous injection of capsaicin resulted in the lowest
average number of labeled neurons per section (2.6 ± 0.6
SEM, n = 6), while wrapping the paw in a gauze soaked
with 25% mustard oil (MO) for 2 hrs induced the highest
number of neurons (50 ± 3.5 SEM, n = 5). On average,
lamina II accounted for 85% ± 3.5 of the labeled neurons,
while lamina I (14% ± 3.2) and III (0.6% ± 0.4) contained
the remaining labeled neurons. The other laminae very
rarely contained labeled neurons.
Expression of Arc/Arg3.1 mRNA following nociceptive
stimulation occurs in a subset of c-Fos labeled neurons
and is intensity dependent
The number of neurons expressing the neuronal acti-
vation marker c-Fos or Arc/Arg3.1 mRNA was
counted in separate sections treated with IHC or ISH,
respectively. c-Fos labeled neurons outnumbered Arc/
Arg3.1 mRNA labeled neurons (Fig. 3A), except after 2
hrs mustard oil stimulation when about equal number
of neurons were labeled. FISH and fluorescent IHC
were applied to simultaneously visualize Arc/Arg3.1
mRNA and c-Fos protein, respectively (Fig. 3B). When
data from the 25% mustard oil and the CFA groups
were taken together (Fig. 3C), 90% ± 6.8 of the Arc/
Arg3.1 mRNA expressing neurons also contained c-Fos
protein. In order to determine whether the number of
Arc/Arg3.1 expressing neurons was stimulus intensity
dependent, rats received a single application (by brush)
of either 10% (n = 5) or 50% (n = 5) mustard oil on
one hind paw. It was found that 50% MO induced sig-
nificantly higher numbers of Arc/Arg3.1 mRNA posi-
tive neurons that 10% mustard oil (Fig. 4A). The
number of c-Fos labeled neurons showed a similar sig-
nificant increase.
Temporal expression of Arc/Arg3.1 mRNA in an acute and
a chronic pain model
As a model for acute pain, 25% MO soaked gauze was
wrapped around one hind paw, with survival times
ranging from 25 min to 8 hrs. The number of Arc/
Arg3.1 mRNA expressing neurons increased over time,
reached a peak at 4 hours and then declined (Fig. 4B).
The distribution of labeled neurons remained
unchanged over time. As a model for chronic pain
CFA was injected in the hind paw, with survival times
ranging from 1.5 hrs to 60 hrs. Temporal expression of
Arc/Arg3.1 mRNA was highest at 1.5 hrs post injection
and then gradually declined (Fig. 4C). No expression of
Arc/Arg3.1 mRNA was found at survival times of 10
hrs and longer. The number of c-Fos expressing neu-
rons was increased at all survival times. In the spared
nerve injury (SNI) model for neuropathic pain, expres-
sion of Arc/Arg3.1 mRNA was only observed at two
hours after the operation. Arc/Arg3.1 mRNA was not
expressed 1 week or 2 weeks after the operation (not
shown) when the neuropathic pain symptoms, i.e.
mechanical and thermal hyperalgesia and allodynia,
had developed. There was no significant difference in
the number of Arc/Arg3.1 mRNA labeled neurons
between the SNI and sham operated group (p>0.05,
unpaired t-test) (Fig. 4D).
Figure 2 Several types of nociceptive stimuli induce Arc/Arg3.1
mRNA in the ipsilateral superficial dorsal horn. Histogram
showing the number of Arc/Arg3.1 mRNA labeled neurons after
each specific nociceptive stimulus. Error bars represent ± SEM.
Hossaini et al. Molecular Pain 2010, 6:43
http://www.molecularpain.com/content/6/1/43
Page 3 of 13
Arc/Arg3.1 mRNA is expressed in specific subpopulations
of dorsal horn neurons
In this experiment, the colocalization of Arc/Arg3.1
with various neuronal markers was investigated (Fig.
5A-E). We found that about a fifth of Arc/Arg3.1
mRNA positive neurons also express the NK-1 recep-
tor (CFA 1.5 hrs: 21.7% ± 7.6, n = 4; MO25%/2 hrs:
17% ± 3.4, n = 5) (Fig. 6). Less than 10% of Arc/
Arg3.1 mRNA expressing neurons also expressed PKC-
g protein (CFA 1.5 hrs: 7.7% ± 3.7, n = 4; MO25%/1h:
9.3% ± 3.8, n = 4). Further, Arc/Arg3.1 mRNA expres-
sing neurons showed a low level of co-existence with
calbindin (CFA 1.5 hrs: 9.7% ± 1.4, n = 4; MO25%/1h:
10.5% ± 2.6, n = 4).
In order to identify Arc/Arg3.1 in inhibitory neurons,
FISH for GAD67 mRNA, the specific marker for
GABAergic neurons, and fluorescent IHC for Arc/
Arg3.1 protein were combined. Very few of the Arc/
Arg3.1 labeled neurons were GABAergic (CFA 3 hrs:
1.7% ± 0.8, n = 4; MO25%/2 hrs: 4.5% ± 0.8, n = 5;
MO25%/4 hrs: 4.5% ± 1.5, n = 4) (Fig. 6). Preproenke-
phalin mRNA is a marker for the subpopulation of
enkephalinergic neurons in the spinal cord. Interestingly,
a large majority of the Arc/Arg3.1 positive neurons also
expressed preproenkephalin mRNA (CFA 3 hrs: 74.2% ±
9.2, n = 4; MO25%/2 hrs: 61.5% ± 2.6, n = 4; MO25%/4
hrs: 68.1% ± 3, n = 4) (Fig. 6).
Intrathecal injection of BDNF induces Arc/Arg3.1 mRNA
expression
Intrathecal injection of brain-derived neurotrophic fac-
tor (BDNF) induced Arc/Arg3.1 mRNA expression in
the superficial dorsal horn neurons (10 ± 1.7/section, n
= 6). We found that 45% ± 8 of Arc/Arg3.1 mRNA
labeled neurons were located in lamina I and 55% ± 8
in lamina II. 93.6% ± 2.5 of Arc/Arg3.1 mRNA labeled
neurons expressed NeuN, 55.6% ± 9.1 expressed c-Fos,
and 16.8% ± 6.4% expressed NK-1. Since it has been
shown [18] that administration of BDNF together with
NBQX, which is an AMPA receptor blocker, increases
Arc/Arg3.1 mRNA expression in cortical neurons, we
injected BDNF intrathecally together with NBQX. This
combination resulted in 13.8 ± 2.9 Arc/Arg3.1 mRNA
labeled neurons/section (n = 6) (Fig. 7A), which was not
significantly different from intrathecal BDNF injection
alone (unpaired t-test). c-Fos expression after BDNF +
NBQX injection was also not significantly different from
BDNF injection alone (p= 0.08 for lamina II) (Fig. 7B).
Intrathecal injection of vehicle (n = 2) or NBQX (n = 2)
alone did not induce Arc/Arg3.1 mRNA expression in
Figure 3 The number of neurons expressing c-Fos outnumber Arc/Arg3.1 mRNA labeled neurons. A, Histogram showing the number of
neurons labeled for c-Fos or Arc/Arg3.1 mRNA following various nociceptive stimuli. capsaicin, n = 6; CFA1.5 hrs, n = 4; MO25%-2 hrs, n = 4;
MO25%-4 hrs, n = 4. B, Fluorescent micrograph showing Arc/Arg3.1 mRNA and/or c-Fos protein labeled neurons in spinal dorsal horn after
stimulation with 25% mustard oil for 2 hours. Arrows indicate Arc/Arg3.1 mRNA labeled neurons that were not in focus and therefore not
included in the analysis. Arrow heads indicate Arc/Arg3.1 mRNA and c-Fos protein labeled neurons. C, Histogram showing the percentage of
Arc/Arg3.1 mRNA labeled neurons that also express the neuronal activation marker c-Fos. Scale bar: 50 μm. Error bars represent ± SEM.
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the spinal cord. Furthermore, we found that intrathecal
injection with NMDA (n = 2), which served as a positive
control, also induced Arc/Arg3.1 expression in the dor-
sal horn (not shown).
Pain behavior in the Arc/Arg3.1 KO mice
Mechanical and thermal thresholds
Freely moving Arc/Arg3.1 knockout (KO) mice did not
display any overt behavioral abnormalities in compari-
son with their wild type (WT) littermates, as reported
previously [13]. With respect to pain behavior, the
mechanical thresholds and hot plate withdrawal laten-
cies were tested. We found that the mechanical thresh-
olds in Arc/Arg3.1 KO mice were not significantly
different from their WT littermates (Fig. 8A). However,
in the hotplate test Arc/Arg3.1 KO mice showed
significantly longer withdrawal latencies than WT mice
(Fig. 8B).
Acute pain: formalin test
Subcutaneous injection of formalin in the hind paw
induced a two-phased pain behavior in both WT and Arc/
Arg3.1 KO mice, consisting of licking and fluttering of the
injected paw. In both groups, the first phase was apparent
in the first 10 minutes after injection, and the second
phase began 25 minutes after injection with licking as the
prominent behavior. No significant difference (repeated-
measures ANOVA, p>0.05) was found between the WT
and Arc/Arg3.1 KO mice in licking or fluttering behavior
(Fig. 9A,B). Also the total licking time (WT: 200 sec. ± 34
(SEM); KO: 275 sec. ± 49 (SEM); p>0.05, unpaired t-test)
nor the total numbers of flutters (WT 100 ± 21 (SEM);
KO 128 ± 32 (SEM); p>0.05, unpaired t-test) were
Figure 4 Arc/Arg3.1 expression is stimulus intensity dependent and is present only in the acute phase of chronic inflammatory and
neuropathic pain. A, Histogram showing the numbers of Arc/Arg3.1 mRNA or c-Fos protein labeled neurons at 2 hours after a brush applied
stimulation with either 10% (n = 5) or 50% (n = 5) mustard oil. * = p < 0.05; ** = p < 0.005 (unpaired t-test). B, Time course of Arc/Arg3.1 mRNA
and c-Fos protein expression after stimulation with 25% mustard oil gauze wrapped around one hind paw for different survival times. 25 min, n
= 4; 45 min, n = 4; 1 h, n = 4; 2 hrs, n = 5; 4 hrs, n = 4; 8 hrs, n = 4. C, Time course of Arc/Arg3.1 mRNA and c-Fos protein expression after CFA
injection in the hind paw. 1.5 hrs, n = 4; 3 hrs, n = 4; 4 hrs, n = 4; 10 hrs, n = 4; 20 hrs, n = 4; 60 hrs, n = 4. D, The number of Arc/Arg3.1 mRNA
labeled neurons 2 hours after sham operation (n = 3) or after cutting the common peroneal and tibial nerves in the SNI model (n = 3). Error
bars represent ± SEM.
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Figure 5 Arc/Arg3.1 is expressed in a subpopulation of superficial dorsal horn neurons with a preference for neurons containing
enkephalin. A-E, Fluorescent micrographs showing neurons in the superficial dorsal horn that express Arc/Arg3.1 mRNA (A-C) or protein (D and
E) and markers that identify neurons expressing the neurokinin-1 receptor (NK1), protein kinase C gamma (PKC-g), Calbindin, GAD67 mRNA
(GABAergic neurons), or preproenkephalin mRNA (enkephalinergic neurons) respectively. The following nociceptive stimuli were used. A, CFA,
survival time 1.5 hrs, B and C: Mustard oil 25% gauze wrapped, survival time 1 h, D and E, Mustard oil 25% gauze wrapped, survival time 2 h.
Arrow heads indicate Arc/Arg3.1 labeled neurons that also express one of the markers mentioned above. Scale bar: 50 μm.
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significantly different. In addition, c-Fos expression due to
the formalin injection did not appear different from the c-
Fos expression in the WT mice.
Chronic pain: inflammation
Induction of chronic inflammation by CFA injection in
the hind paw resulted in decreased mechanical thresh-
olds of the injected paw (Fig. 10A). A repeated measures
ANOVA did not reveal any significant differences
between WT and Arc/Arg3.1 KO mice regarding the
mechanical or thermal thresholds at any time point (Fig.
10A,B).
Discussion
In this study we have used in situ hybridization (ISH) and
immunohistochemistry (IHC) to show that nociceptive sti-
mulation induced Arc/Arg3.1 mRNA and protein in the
superficial dorsal horn of the spinal cord. Both techniques
specifically identified Arc/Arg3.1 since standard controls,
most notably nociceptively stimulated spinal cord of Arc/
Arg3.1 knockout (KO) mice, did not show any specific
labeling. In naïve or vehicle treated animals expression of
Arc/Arg3.1 mRNA and protein was absent in the spinal
cord, in agreement with a study using RT-PCR [19]. This
strongly indicates that in the spinal cord a nociceptive sti-
mulus induces de novo expression of Arc/Arg3.1, in con-
trast with other areas of the nervous system, like
hippocampus [17] and cortex [20].
Arc/Arg3.1 mRNA and protein were induced in the
superficial dorsal horn in the acute phases of all pain
models that we tested, i.e. after nociceptive stimulation
with capsaicin, CFA, formalin and mustard oil. Injection
of CFA induces an inflammatory process [21] that leads
to the release of cytokines and other local messengers,
all of which may activate different types of receptors on
nociceptive fibers. Capsaicin, however, specifically acti-
vates nociceptive fibers expressing the transient receptor
potential vanilloid-1 (TRPV1) [22]. Further, mustard oil
and formalin both specifically activate the TRPA1 recep-
tor, although formalin may exert TRPA1-independent
effects at higher concentrations [23,24]. The number of
neurons producing Arc/Arg3.1 mRNA varied in the dif-
ferent pain models, and increasing the intensity of the
pain stimulus resulted in an increased number of neu-
rons expressing Arc/Arg3.1 as shown in the mustard oil
experiments. Therefore, our data indicate that the num-
ber of neurons expressing Arc/Arg3.1 depends on the
intensity of the stimulus, but is not limited to the activa-
tion of one specific receptor on peripheral nerves.
Neurons expressing Arc/Arg3.1 in the spinal cord are
most likely driven by direct input from afferent
Figure 6 Histogram showing the averaged percentages of
neurons expressing Arc/Arg3.1(induced after various
nociceptive stimuli, as in fig. 5), that co-express either NK1,
PKC-g, Calbindin, GAD67 mRNA or preproenkephalin mRNA.
Error bars represent ± SEM. For details, see text.
Figure 7 Intrathecal injection of BDNF induces Arc/Arg3.1 mRNA expression in spinal dorsal horn. A and B, The averaged number of
neurons that express Arc/Arg3.1 mRNA (A) or c-Fos protein (B) after intrathecal injection with BDNF or BDNF together with NBQX. Error bars
represent ± SEM.
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nociceptive fibers that use glutamate as their main neu-
rotransmitter [25]. Apart from glutamate and various
neuropeptides, these fibers may also contain growth fac-
tors like BDNF [26] or GDNF [27]. We found that
intrathecal injection of NMDA or BDNF induced Arc/
Arg3.1 mRNA in spinal dorsal horn neurons. This is in
line with Arc/Arg3.1 expression in cultured neurons fol-
lowing BDNF application [18]. The same study showed
a significantly enhanced expression of Arc/Arg3.1
mRNA when NBQX, a potent AMPA receptor blocker,
was applied together with BDNF. However, in the pre-
sent study a significant increase in the number of Arc/
Arg3.1 mRNA expressing neurons could not be con-
firmed after intrathecal injection of BDNF and NBQX
together. Taken together, our findings are in line with
the idea that release of glutamate and/or BDNF from
activated nociceptive fibers are at least partly responsible
for Arc/Arg3.1 induction in the spinal dorsal horn.
Following nociceptive stimulation, Arc/Arg3.1 was
often expressed in activated neurons as identified by c-
Fos. Especially after nociceptive stimulation with capsai-
cin, and after chronic inflammatory pain, the number of
neurons expressing Arc/Arg3.1 is low as compared to
those showing c-Fos expression. This finding may be
interpreted to indicate that Arc/Arg3.1 is only expressed
in activated neurons that received the strongest input
from nociceptive fibers. This assumption is in line with
our finding that Arc/Arg3.1 expression is intensity
dependent. On the other hand, there may be specific
subpopulations of spinal nociceptive neurons that are
capable of producing Arc/Arg3.1, while others are not.
In search of such a neuronal subpopulation that specifi-
cally expressed Arc/Arg3.1, we focused on neurons that
were characterized by the expression of the neurokinin-
1 (NK-1) receptor, Protein Kinase C gamma (PKC-g),
calbindin, GAD67 or preproenkephalin. We found a
high percentage of Arc/Arg3.1 expressing neurons (68%)
to contain preproenkephalin, while percentages of colo-
calization with other markers were less prominent (19%
for NK-1; 8.5% for PKC-g; 3.6% for GAD67; 10% for cal-
bindin). NK-1 expressing neurons project to supraspinal
sites [28] and are essential for the initiation and mainte-
nance of chronic neuropathic and inflammatory pain
[29], and neurons expressing PKC-g are considered criti-
cally important for the development of neuropathic pain
after peripheral nerve injury [30]. The finding that only
a small number of Arc/Arg3.1 positive neurons also
expressed NK-1 or PKC-g indicates that Arc/Arg3.1 is
Figure 8 Naïve Arc/Arg3.1 knockout (KO) mice showed
significantly longer response times on the hotplate than their
naïve wild type (WT) littermates. A and B, Histogram showing
the mechanical threshold (A) and thermal withdrawal latency (B) of
Arc/Arg3.1 KO and WT mice, assessed with the Von Frey and the
hotplate test, respectively. Error bars represent ± SEM. *: p < 0.05,
unpaired t-test; n = 4 for A and for B.
Figure 9 Arc/Arg3.1 KO mice do not differ from WT mice concerning licking or fluttering of the paw injected with formalin. A and B,
Graphs showing the time spent licking (A) and the number of flutters (B) after formalin injection in the hind paw during an observation period
of 55 minutes. Error bars represent ± SEM. Differences were not significant (repeated-measures ANOVA, p>0.05). n = 4 for A and for B.
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not strongly involved in pain processing by the NK-1 or
PKC-g subpopulations of dorsal horn neurons. This is
remarkable since especially the NK-1 expressing neu-
rons projecting to the parabrachial area or periaqueduc-
tal grey show LTP formation after high or low
frequency stimulation, respectively [31]. Our finding
indicates that Arc/Arg3.1 dependent long term changes
may occur preferentially in local interneurons rather
than in projection neurons. Further, we found low colo-
calization with GAD67, the marker for GABAergic neu-
rons, indicating that the expression of Arc/Arg3.1 is low
in the total subpopulation of dorsal horn inhibitory neu-
rons since glycinergic neurons are virtually absent in the
superficial dorsal horn [32-34], and, if present, also con-
tain GABA [35]. In the hippocampal and neocortical
neurons expression of Arc/Arg3.1 in GABAergic posi-
tive neurons is also low but this is not the case in the
dorsal striatum [20]. Together, NK-1, PKC-g and/or pre-
proenkephalin constitute more than 90% of the Arc/
Arg3.1 expressing neurons. Since to date there is no evi-
dence for the colocalization of these substances with
each other, we conclude that Arc/Arg3.1 is preferentially
expressed in the subpopulation of enkephalinergic neu-
rons. Preproenkephalin mRNA is the precursor of both
Met- and Leu-enkephalin, which are both expressed by
neurons in the spinal cord and mainly exert their effect
on the δ-opioid receptor (DOR) [36]. Also, preproenke-
phalin mRNA in the spinal cord is increased after per-
ipheral inflammation and is also present in neurons that
express c-Fos after nociceptive stimuli [37]. Further,
using VgluT2 immunohistochemistry for identifying glu-
tamatergic terminals, it was shown [38] that 85% of the
enkephalin containing terminals in the dorsal horn use
glutamate as transmitter. However, a study [39] using
cultured dorsal horn neurons showed 42% colocalization
of immunohistochemically identified GAD and enkepha-
lin. A more recent study [40] using preproenkephalin
green fluorescent protein transgenic mice, showed that
43% of the fluorescent enkephalin neurons also
expressed immunohistochemically identified GABA.
Colocalization of enkephalin with VgluT2 was not
explored in these studies. Since we found a low level of
colocalization of Arc/Arg3.1 with GABAergic neurons,
it is not unlikely that several of the enkephalinergic neu-
rons in the spinal cord that express Arc/Arg3.1 also use
glutamate as a transmitter. The functional role of gluta-
mate in these fibers is unclear, since it is not known
whether they activate inhibitory or excitatory (i.e. anti-
or pro-nociceptive) circuits in the spinal cord, nor is it
known under which circumstances enkephalin and/or
glutamate is released from these fibers. Since the activa-
tion of the delta opioid receptor (DOR), through which
enkephalin exerts its effect, decreases pain behavior dur-
ing chronic peripheral inflammation [41], we tend to
conclude that the overall effect of Arc/Arg3.1 expressing
enkephalinergic neurons is anti-nociceptive.
In order to understand the functional role of Arc/
Arg3.1 in enkephalinergic neurons at the behavioral
level, we employed Arc/Arg3.1 KO mice and their WT
littermates. The only significant difference between
these mice was that in the hotplate test the thermal
threshold of naïve Arc/Arg3.1 KO mice was significantly
higher as compared to naïve WT mice. This finding is
difficult to interpret since naïve WT mice, like their KO
littermates, do not show Arc/Arg3.1 expression in the
spinal cord. One explanation may be that there is a very
low basal expression of Arc/Arg3.1 that we and others
[19] were not able to detect, and that the permanent
lack of Arc/Arg3.1 in the KO mice may have altered
spinal processing of nociceptive thermal stimuli over
time. Alternatively there may be supraspinal changes in
nociceptive processing. After nociceptive stimuli, we did
not find any difference in the pain behavior between the
KO and WT mice in the formalin test and chronic
inflammatory pain model. We therefore conclude that
Arc/Arg3.1 KO mice do not show a clear phenotypic
change that can be attributed to pain transmission in
the spinal cord.
Figure 10 No differences in mechanical and thermal thresholds between the Arc/Arg3.1 KO and WT mice during the time course of
inflammatory pain. A and B, Graphs showing mechanical (A) and thermal (B) thresholds after CFA injection in one hind paw of Arc/Arg3.1 KO
and WT mice. Differences were not significant at any time point (repeated-measures ANOVA, p>0.05). n = 4 for A and for B.
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Several studies have shown that in hippocampus
knockdown of Arc/Arg3.1 leads to enhanced LTP in the
early phase but impaired consolidation of LTP and long
term depression (LTD) in the late phase [13]. In the
spinal cord, LTP is one of the major components of
central sensitization [16], especially in lamina I project-
ing neurons [31]. LTP leads to enhanced responsiveness
of spinal nociceptive neurons, which is important for
maintenance of hyperalgesia and allodynia during acute
and chronic pain. Our finding that Arc/Arg3.1 KO mice
develop hypersensitivity in acute and chronic pain mod-
els in the same way as their WT littermates, suggests
that the LTP formation that contributes to central sensi-
tization and subsequent developing hyperalgesia is unaf-
fected by the lack of Arc/Arg3.1. It seems therefore that
Arc/Arg3.1 is not critically involved in LTP as occurring
in the dorsal horn projection neurons, which in line
with our result that few NK-1 positive neurons express
Arc/Arg3.1.
The low number of spinal projection neurons that
express Arc/Arg3.1 may be explained by the fact that, in
contrast to other areas of the brain, structural long-term
changes in the excitability of these spinal neurons are
counterproductive if they persist after the healing pro-
cess has been completed. Our finding that Arc/Arg3.1 is
expressed predominantly in enkephalinergic neurons
may suggest that in these neurons long term changes
are actually consolidated. However, Arc/Arg3.1 KO mice
that lack consolidation of long term changes show nor-
mal pain behavior. This would not exclude that enke-
phalinergic neurons, which have an inhibitory effect on
pain transmission, may serve as an anti-nociceptive
mechanism against strong nociceptive inputs that may
occur in the future.
Conclusions
Our data show that Arc/Arg3.1, which is critically
involved in consolidating long term structural changes
in the forebrain, is preferentially induced in spinal enke-
phalinergic neurons after nociceptive stimulation. This
finding suggests that Arc/Arg3.1 dependent memory
formation in spinal pain transmission is a predominant
feature of neurons, which are anti-nociceptive rather
than pro-nociceptive.
Methods
Animal experiments
In this study we used 99 male Wistar rats and 16 Arc/
Arg3.1 KO mice and their wild type littermates.
Rats
50 μl of 0.3% capsaicin (Sigma-Aldrich) solution consist-
ing of 80% saline, 10% Tween-80, and 10% ethanol 100%
(n: 6; survival: 1.5 hrs) or 100 μl of Complete Freund’s
Adjuvant (CFA, Sigma-Aldrich; n: 24; survival: 1.5 hrs, 3
hrs, 4 hrs, 10 hrs, 20 hrs, 60 hrs) was injected in a hind
paw under anesthesia with 2% isofluorane in 30%O2/70%
N2O. In experiments applying mustard oil (MO) (Allyli-
sothiocyanat, Merck) the animals were kept under
anesthesia during entire survival time and subsequent
perfusion. For 25% MO application (n: 25; survival: 25
min, 45 min, 1 h, 2 hrs, 4 hrs, 8 hrs) the left paw was
shaved and wrapped in a gauze soaked with MO and
then covered with foil. For application of 10% (n: 5; survi-
val: 2 hrs) and 50% (n: 5, survival: 2 hrs) MO, the left paw
was shaved and MO was applied once at the beginning of
the experiment using a brush. For the experiments using
intrathecal injections, the same protocol was used as
described in [42]. Brain-derived neurotrophic factor
(BDNF, 10 μg, Tocris) was injected intrathecally in a total
injection volume of 40 μl (n: 6; survival: 75 min). In
another experiment, 5 μg of 1,2,3,4-tetrahydro-6-nitro-
2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide (NBQX,
Tocris) was injected concomitantly with BDNF (n: 6; sur-
vival: 75 min). For control intrathecal experiments, 25
nmol N-Methyl-d-asparate (NMDA; Sigma, St. Louis,
MO; n: 2; survival: 75 min), or only vehicle (1% bovine
serum albumin in 0.025 M phosphate buffer; n: 2; survi-
val: 75 min) or only NBQX (n: 2; survival: 75 min) was
injected intrathecally. After the injections, the rats were
placed back in their cages. For induction of neuropathic
pain, the spared nerve injury (SNI) model and a control
operation were used [43]. In short, the sciatic nerve was
exposed and the three branches were isolated. The tibial
and the common peroneal branches were ligated and
then cut while the sural nerve was left intact (n: 9; survi-
val: 2 hrs, 7 days, 14 days). As a control, the sciatic nerve
was only exposed and isolated (n:7; survival: 2 hrs, 7 days,
14 days).
Arc/Arg3.1 KO and WT mice
All mice were habituated for 5 days to the experimenter,
the experiment room, and the transparent cage that was
used for the Von Frey measurements. Thereafter, prior
to each experiment the mice were habituated for 30
minutes to the room in which the behavioral experi-
ments took place.
Von Frey experiment before each Von Frey measure-
ment, the mice were allowed to habituate to a transpar-
ent cage (15 cm × 15 cm with a gridded floor) for 10
minutes. We used calibrated von Frey filaments, which
were applied for 2 seconds at 5 seconds interval, and
the threshold was set at 3 evoked responses in a maxi-
mum of 5 applications.
Hotplate test the thermal thresholds were assessed by
measuring the time a mouse spent on the hotplate (51°
C) before showing a response like fluttering or licking of
the hind paw, or jumping. Immediately after a response
or after maximally 45 seconds, the mouse was taken off
the hotplate.
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The formalin pain model the mice were restrained by
the experimenter and 15 μl of formalin, i.e. a freshly
made solution of 4% paraformaldehyde (PFA) in phos-
phate buffer (PB), was injected subcutaneously in the
left hind paw. The number of flutters and the time
spent licking of the injected paw were measured during
55 minutes post-injection. After 90 minutes the mice
were perfused and the tissue was processed as described
below. n = 4 for Arc/Arg3.1 KO mice; n = 4 for WT
littermates.
The CFA pain model 25 μl of CFA was injected in a
hind paw of restrained mice and thereafter the mechani-
cal and thermal thresholds were assessed at 1.5 h, 4 hrs,
1 d, 3 d, 4 d, 8 d, 14 d, 21 d, 28 d, 34 d, and 42 d post-
injection. n = 4 for Arc/Arg3.1 KO mice; n = 4 for WT
littermates.
Statistical analysis An unpaired t-test or a repeated
measures ANOVA was performed, p < 0.05 was taken
as significant.
Examination of the Arc/Arg3.1 KO mice spinal tissue
After experiments the mice were sacrificed and further
processed for immunohistochemistry (IHC) or in situ
hybridization (ISH). Histological examination of Arc/
Arg3.1 KO mice spinal cord did not reveal any morpho-
logical abnormalities in comparison with their WT
littermates.
Tissue preparation
At the end of the survival times the animals received an
overdose of sodium pentobarbital and were transcar-
dially perfused with 100 ml saline (rats) or 10 ml (mice)
followed by 750 ml of 4% PFA (rats) or 50 ml (mice)
dissolved in 0.12 M phosphate buffer (PB), pH 7.4. The
spinal cord was dissected and left overnight in a solution
of 4% PFA and 30% sucrose at 4°C. Subsequently, sec-
tions were cut (30 μm) on a freezing microtome and
collected in RNAse-free PB. Serial sections were cut and
collected in 9 separate jars, and therefore sections in
one jar were at least 270 μm apart. The sections were
kept in a solution of 40% glycerol, 40% ethyleenglycol
and 20% RNAse-free PB for long-term storage at -20°C.
In situ hybridization and immunohistochemistry
The partial cDNA templates encoding the following
mRNAs were used: Arc/Arg3.1 (3.5 kb, full length probe
encoding the mus musculus Arc/Arg3.1 gene, GeneID:
11838; Image Clone number: 3498057), GAD67 (3.2 kb;
a generous gift from Dr. A.J. Tobin, UCLA), preproen-
kephalin (0.95 kb, a generous gift from Dr. S.L. Sabol,
NIH). The riboprobes were obtained by linearizing the
recombinant plasmids with the appropriate restriction
enzymes and RNA polymerases. The transcription was
performed in the presence of digoxigenin (DIG)- or
fluorescein-labeled 11-UTP (Roche). ISH based on
alkalic phosphatase (AP) reaction was performed follow-
ing the protocol described previously [32]. For fluores-
cent in situ hybridization (FISH) the following
modifications were applied to the protocol. After ribop-
robe hybridization, the detection of DIG or fluorescein
was achieved with sheep polyclonal anti-Dig antibody
(Roche) or mouse monoclonal anti-fluorescein antibody
(Roche), respectively (1:500; 48 hours at 4°C in phos-
phate buffer saline (PBS), 2% milk powder and 0.5% Tri-
ton X-100). Thereafter, the anti-DIG or anti-fluorescein
primary antibodies were detected using biotinylated rab-
bit-anti-goat (Vector) or goat-anti-mouse (Vector),
respectively. Subsequently, the sections were incubated
with Avidin-Biotin-Complex (ABC, Vector) tagged with
horseradish peroxidase (HRP). A tyramide amplification
procedure was performed by reacting HRP with H2O2
and a self made FITC tyramide according to protocol
described in [44]. Thereafter, the sections were washed
in PBS and processed for fluorescent IHC using the fol-
lowing antibodies diluted in 2% milk power solution:
rabbit anti-Arc (1/3000; a generous gift from Dr. D.
Kuhl), rabbit anti-c-Fos (1: 40.000; Oncogene Research
Products, La Jolla, CA), rabbit anti-neurokinin-1 (NK1;
1:5000; Advanced Targeting System, CA, USA), rabbit
anti-calbindin (1:7000; Swant, Switzerland), rabbit anti-
PKC-g (1/750; Santa Cruz), and mouse anti-neuronal
nuclei (NeuN) monoclonal antibody (1:5000, Chemicon).
These primary antibodies were detected with Cy3 tagged
fluorescent secondary antibodies donkey-anti-rabbit or
donkey-anti-mouse (1:200). Thereafter, the section were
washed in PB and mounted on slides and coverslipped
with Vectashield (Vector).
Data analysis
Analysis was carried out on L4 and L5 segments of the
spinal cord, except for the BDNF experiments, in which
also S1 and S2 segments were included in the analysis.
Slides were systematically examined starting from the
first section in the first row for the appropriate segmen-
tal level. The first 5 to 6 sections that were encountered
and were not damaged during the procedure were
included in the analysis [42]. For illustrations, light
micrographs were made with a digital camera and con-
focal images with a Zeis LSM 510 confocal laser scan-
ning microscope and a 20× objective. The images were
processed using Adobe Photoshop and were not
manipulated, except for brightness and contrast. Quanti-
tative analysis of Arc/Arg3.1 mRNA positive neurons
based on AP-ISH was achieved using a camera lucida
microscope (Neurolucida, Microbrightfield Inc., Willis-
ton, VT). The grey and white matter and the boundaries
between the laminae were drawn according to [45] and
labeled neurons were identified only if the largest dia-
meter was at least 10 μm, and the cell soma contained a
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bluish/brownish product. Labeled neurons were
expressed as the average number of labeled neurons per
section.
For double labeling based on FISH combined with
fluorescent IHC, confocal images were analyzed using
the Zeis LSM image browser. For each section, the dor-
sal horn showing Arc/Arg3.1 labeled neurons was ana-
lyzed in a vertical plane consisting of 9 slices with an
optical thickness of 2.46-2.76 μm. Every fifth section
was analyzed for double labeled neurons. For markers
that label the cytoplasm, the criterion was that the dia-
meter of a profile was at least 10 μm to be counted as a
neuron. For statistical analysis, an unpaired t-test was
performed, and p < 0.05 considered significant.
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